Skip to content
LexBuild

Title 21, Part 310 — New Drugs

37 sections

Section 310.3
Definitions and interpretations.
Section 310.4
Biologics; products subject to license control.
Section 310.6
Applicability of “new drug” or safety or effectiveness findings in drug efficacy study implementation notices and notices of opportunity for hearing to identical, related, and similar drug products.
Section 310.100
New drug status opinions; statement of policy.
Section 310.103
New drug substances intended for hypersensitivity testing.
Section 310.200
Prescription-exemption procedure.
Section 310.201
Exemption for certain drugs limited by new-drug applications to prescription sale.
Section 310.305
Records and reports concerning adverse drug experiences on marketed prescription drugs for human use without approved new drug applications.
Section 310.306
Notification of a permanent discontinuance or an interruption in manufacturing of marketed prescription drugs for human use without approved new drug applications.
Section 310.501
Patient package inserts for oral contraceptives.
Section 310.502
Certain drugs accorded new drug status through rulemaking procedures.
Section 310.503
Requirements regarding certain radioactive drugs.
Section 310.509
Parenteral drug products in plastic containers.
Section 310.515
Patient package inserts for estrogens.
Section 310.517
Labeling for oral hypoglycemic drugs of the sulfonylurea class.
Section 310.518
Drug products containing iron or iron salts.
Section 310.519
Drug products marketed as over-the-counter (OTC) daytime sedatives.
Section 310.527
Drug products containing active ingredients offered over-the-counter (OTC) for external use as hair growers or for hair loss prevention.
Section 310.528
Drug products containing active ingredients offered over-the-counter (OTC) for use as an aphrodisiac.
Section 310.529
Drug products containing active ingredients offered over-the-counter (OTC) for oral use as insect repellents.
Section 310.530
Topically applied hormone-containing drug products for over-the-counter (OTC) human use.
Section 310.531
Drug products containing active ingredients offered over-the-counter (OTC) for the treatment of boils.
Section 310.532
Drug products containing active ingredients offered over-the-counter (OTC) to relieve the symptoms of benign prostatic hypertrophy.
Section 310.533
Drug products containing active ingredients offered over-the-counter (OTC) for human use as an anticholinergic in cough-cold drug products.
Section 310.534
Drug products containing active ingredients offered over-the-counter (OTC) for human use as oral wound healing agents.
Section 310.536
Drug products containing active ingredients offered over-the-counter (OTC) for use as a nailbiting or thumbsucking deterrent.
Section 310.537
Drug products containing active ingredients offered over-the-counter (OTC) for oral administration for the treatment of fever blisters and cold sores.
Section 310.538
Drug products containing active ingredients offered over-the-counter (OTC) for use for ingrown toenail relief.
Section 310.540
Drug products containing active ingredients offered over-the-counter (OTC) for use as stomach acidifiers.
Section 310.541
Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hypophosphatemia.
Section 310.542
Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia.
Section 310.543
Drug products containing active ingredients offered over-the-counter (OTC) for human use in exocrine pancreatic insufficiency.
Section 310.544
Drug products containing active ingredients offered over-the-counter (OTC) for use as a smoking deterrent.
Section 310.545
Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses.
Section 310.546
Drug products containing active ingredients offered over-the-counter (OTC) for the treatment and/or prevention of nocturnal leg muscle cramps.
Section 310.547
Drug products containing quinine offered over-the-counter (OTC) for the treatment and/or prevention of malaria.
Section 310.548
Drug products containing colloidal silver ingredients or silver salts offered over-the-counter (OTC) for the treatment and/or prevention of disease.